AR026356A1 - Metodo para tratar la diabetes - Google Patents
Metodo para tratar la diabetesInfo
- Publication number
- AR026356A1 AR026356A1 ARP000105805A ARP000105805A AR026356A1 AR 026356 A1 AR026356 A1 AR 026356A1 AR P000105805 A ARP000105805 A AR P000105805A AR P000105805 A ARP000105805 A AR P000105805A AR 026356 A1 AR026356 A1 AR 026356A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetes
- treat diabetes
- post
- treatment
- prandial
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 230000000291 postprandial effect Effects 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/432,465 US6586438B2 (en) | 1999-11-03 | 1999-11-03 | Antidiabetic formulation and method |
| US09/460,920 US7598262B2 (en) | 1999-11-03 | 1999-12-14 | Method for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR026356A1 true AR026356A1 (es) | 2003-02-05 |
Family
ID=27029501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105805A AR026356A1 (es) | 1999-11-03 | 2000-11-03 | Metodo para tratar la diabetes |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1229918B1 (enExample) |
| JP (1) | JP5183844B2 (enExample) |
| KR (1) | KR20070089259A (enExample) |
| CN (1) | CN1450902A (enExample) |
| AR (1) | AR026356A1 (enExample) |
| AT (1) | ATE390140T1 (enExample) |
| AU (1) | AU780106B2 (enExample) |
| BR (1) | BR0015294A (enExample) |
| CA (1) | CA2389928C (enExample) |
| EE (1) | EE05260B1 (enExample) |
| HU (1) | HU229352B1 (enExample) |
| IL (1) | IL149139A0 (enExample) |
| LT (1) | LT5058B (enExample) |
| LV (1) | LV12910B (enExample) |
| MX (1) | MXPA02004282A (enExample) |
| NO (1) | NO330026B1 (enExample) |
| NZ (1) | NZ518278A (enExample) |
| PL (1) | PL199278B1 (enExample) |
| RU (1) | RU2275915C2 (enExample) |
| SK (1) | SK287810B6 (enExample) |
| TW (1) | TWI280125B (enExample) |
| UY (1) | UY26424A1 (enExample) |
| WO (1) | WO2001032157A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7563774B2 (en) | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| FR2816840B1 (fr) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
| FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
| WO2003011273A1 (en) * | 2001-07-31 | 2003-02-13 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Metformin in the treatment of hyperglycemic conditions |
| EP1492511B3 (fr) | 2002-04-09 | 2012-05-02 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
| EP1515701B1 (en) | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide |
| CA2544245A1 (en) * | 2003-10-30 | 2005-05-26 | Tioga Pharmaceuticals, Inc. | Use of selective opiate receptor modulators in the treatment of neuropathy |
| MXPA06007100A (es) * | 2003-12-19 | 2007-01-19 | Omega Bio Pharma Ip3 Ltd | Composiciones y metodos para tratar la diabetes. |
| JP4976281B2 (ja) * | 2004-05-03 | 2012-07-18 | オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド | 代謝を調節するための材料および方法 |
| JO3272B1 (ar) | 2007-07-19 | 2018-09-16 | Takeda Pharmaceuticals Co | مستحضر صلب يشمل ألوجليبتين وميتفورمين هيدروكلوريد |
| CA2699285C (en) | 2007-09-10 | 2016-12-13 | Ahmed F. Abdel-Magid | Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt) |
| RU2372911C1 (ru) * | 2008-03-12 | 2009-11-20 | Николай Евгеньевич Староверов | Полиморфная аналоговая терапия |
| LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| SG185525A1 (en) | 2010-05-11 | 2012-12-28 | Janssen Pharmaceutica Nv | Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| CN107375909A (zh) * | 2011-02-02 | 2017-11-24 | 赛诺菲-安万特德国有限公司 | 在2型糖尿病患者中预防低血糖症 |
| US20120277147A1 (en) * | 2011-03-29 | 2012-11-01 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| MA41138B1 (fr) | 2014-12-12 | 2023-07-31 | Sanofi Aventis Deutschland | Formulation à rapport fixe d'insuline glargine/lixisenatide |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| CN110804017A (zh) * | 2019-10-31 | 2020-02-18 | 天津大学 | 磺酰脲化合物与二甲双胍成盐、制备方法和应用 |
| CN113143940A (zh) * | 2020-12-30 | 2021-07-23 | 成都恒瑞制药有限公司 | 一种抗糖尿病药物组合物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| DE3833439A1 (de) * | 1988-10-01 | 1991-09-12 | Hoechst Ag | Verfahren zur mikronisierung von glibenclamid |
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| IT1276130B1 (it) * | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
| WO1998057634A1 (en) | 1997-06-18 | 1998-12-23 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and metformin |
| ES2216335T3 (es) * | 1997-12-08 | 2004-10-16 | Bristol-Myers Squibb Company | Nuevas sales de metformina y procedimiento. |
| ES2206868T3 (es) * | 1998-07-15 | 2004-05-16 | Merck Sante | Comprimidos que comprenden una combinacion de metformin glibenclamida. |
| EP2620443A1 (en) | 2012-01-25 | 2013-07-31 | Galecto Biotech AB | Novel galactoside inhibitors of galectins |
-
2000
- 2000-10-13 IL IL14913900A patent/IL149139A0/xx unknown
- 2000-10-13 MX MXPA02004282A patent/MXPA02004282A/es active IP Right Grant
- 2000-10-13 HU HU0300218A patent/HU229352B1/hu unknown
- 2000-10-13 NZ NZ518278A patent/NZ518278A/en not_active IP Right Cessation
- 2000-10-13 WO PCT/US2000/028311 patent/WO2001032157A2/en not_active Ceased
- 2000-10-13 EP EP00972122A patent/EP1229918B1/en not_active Expired - Lifetime
- 2000-10-13 AT AT00972122T patent/ATE390140T1/de not_active IP Right Cessation
- 2000-10-13 CA CA2389928A patent/CA2389928C/en not_active Expired - Lifetime
- 2000-10-13 AU AU10826/01A patent/AU780106B2/en not_active Expired
- 2000-10-13 PL PL364885A patent/PL199278B1/pl unknown
- 2000-10-13 JP JP2001534362A patent/JP5183844B2/ja not_active Expired - Fee Related
- 2000-10-13 KR KR1020077018914A patent/KR20070089259A/ko not_active Withdrawn
- 2000-10-13 CN CN00818032A patent/CN1450902A/zh active Pending
- 2000-10-13 RU RU2002114820/14A patent/RU2275915C2/ru active
- 2000-10-13 EE EEP200200242A patent/EE05260B1/xx unknown
- 2000-10-13 SK SK500-2002A patent/SK287810B6/sk not_active IP Right Cessation
- 2000-10-13 BR BR0015294-3A patent/BR0015294A/pt not_active Application Discontinuation
- 2000-10-27 TW TW089122713A patent/TWI280125B/zh not_active IP Right Cessation
- 2000-11-02 UY UY26424A patent/UY26424A1/es not_active Application Discontinuation
- 2000-11-03 AR ARP000105805A patent/AR026356A1/es unknown
-
2002
- 2002-05-02 NO NO20022087A patent/NO330026B1/no not_active IP Right Cessation
- 2002-05-24 LT LT2002063A patent/LT5058B/lt not_active IP Right Cessation
- 2002-06-03 LV LVP-02-94A patent/LV12910B/lv unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR026356A1 (es) | Metodo para tratar la diabetes | |
| Hamada et al. | Electrical stimulation of human lower extremities enhances energy consumption, carbohydrate oxidation, and whole body glucose uptake | |
| TNSN00206A1 (en) | Method for treating diabetes | |
| MY155270A (en) | Use of glp-1 or analogs in treatment of stroke | |
| EA200000747A1 (ru) | СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА | |
| BR0109336A (pt) | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico | |
| FI3524261T3 (fi) | Exendin käytettäväksi diabeteksen hoidossa ja ruumiin painon vähentämiseksi | |
| DE60036367D1 (de) | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes | |
| DE60334147D1 (de) | Plazentäre alkalische phosphatase zur diabeteskontrolle | |
| DE50110262D1 (de) | Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen | |
| DK30092A (da) | Fremgangsmaade og midler til ikke-invasiv aedosis-til-virkningae administration af lipofile laegemidler | |
| ATE409042T1 (de) | Verwendung von sulodexide zur behandlung von diabetischer nephropathie | |
| BR0104586A (pt) | Método para tratamento de neurodegeneração | |
| ES2182840T3 (es) | Factor xiii para el tratamiento de heridas de la piel. | |
| RU2004103531A (ru) | Фармацевтическая композиция для перорального применения, содержащая одновременно метформин и гликлазид | |
| RU2002120168A (ru) | Способ лечения ишемических заболеваний глаз | |
| RU2002109173A (ru) | Способ лечения дистрофических заболеваний сетчатой оболочки глаза | |
| SE9101341D0 (sv) | New medicinal use | |
| CN1169562C (zh) | 用于跌打损伤恢复期的外用膏药 | |
| MX2021014997A (es) | Agente de vanadio y metformina como principio activo para el tratamiento de padecimientos relacionados con la resistencia a la insulina. | |
| RU2001103672A (ru) | Способ лечения больных артериальной гипертензией | |
| US20030198686A1 (en) | Chinese medicinal composition | |
| RU2003108517A (ru) | Способ лечения колибактериоза и сальмонеллеза у поросят | |
| RU2004111044A (ru) | Препарат для лечения геморрагического инсульта и способ лечения геморрагического инсульта | |
| RU2003104738A (ru) | Способ лечения больных сахарным диабетом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |